Alfredo Arellano
Psychiatric/Mental Health · El Paso, TXNPI 1851558266
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,613 of the $54,685 with a category attached, or 63.3%. 18 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 59.9% of the total. 2025 is the largest year on record at $33,780, more than ten times the $1,061 reported in 2021. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 399 payments — averaging $137.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$33K
- Axsome Therapeutics, Inc.$16K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$826
- Alkermes, Inc.$813
- Neurocrine Biosciences, Inc.$753
- plus $2K from 12 others
What the payments were for
- Consulting fees$4,4608%
- Speaking & faculty fees$34,61363%
- Travel & lodging$5,54210%
- Food & beverage$9,96518%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 133 | $32,770 |
| Axsome Therapeutics, Inc. | 43 | $16,184 |
| Teva Pharmaceuticals USA, Inc. | 36 | $1,391 |
| AbbVie | 44 | $826 |
| Alkermes, Inc. | 26 | $813 |
| Neurocrine Biosciences, Inc. | 37 | $753 |
| Lundbeck LLC | 21 | $400 |
| Johnson & Johnson | 10 | $392 |
| Vanda Pharmaceuticals Inc. | 12 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $206 |
| Idorsia Pharmaceuticals US Inc | 8 | $178 |
| E.r. Squibb & Sons, L.L.C. | 4 | $154 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| C2n Diagnostics, LLC | 1 | $74 |
| Sunovion Pharmaceuticals Inc. | 5 | $54 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $18 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,685 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $142,225 |
| CaplytaLumateperone Tosylate | 40 | $69,108 |
| AristadaAripiprazole Lauroxil | 12 | $47,350 |
| VraylarCariprazine Hcl | 16 | $23,641 |
| LinzessLinaclotide | 15 | $11,409 |
| Paliperidone ErPaliperidone | 15 | $10,530 |
| QuviviqDaridorexant Hcl | 12 | $5,953 |
| Aripiprazole | 36 | $3,375 |
| Quetiapine Fumarate | 110 | $2,538 |
| Mirtazapine | 79 | $2,380 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $2,332 |
| Donepezil Hcl | 31 | $2,034 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 75 | $1,856 |
| Zolpidem Tartrate | 104 | $1,778 |
| Bupropion XlBupropion Hcl | 62 | $1,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $753 | $142,22517 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $32,770 | $69,10840 claims |
| Alkermes, Inc.Aristada | $813 | $47,35012 claims |
| AbbVieVraylar, Linzess | $826 | $35,05031 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $178 | $5,95312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in El Paso
- Victor IlogEl Paso$167K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.